Examkin

Question

Difficulty: HardHematology and Oncology

A 35-year-old woman presents to the emergency department with a sudden onset of severe epistaxis, diffuse petechiae, and profound fatigue. Her initial complete blood count reveals a leukocyte count of 24,000/mm³, hemoglobin of 7.8 g/dL, and a platelet count of 15,000/mm³. Based on the acuity and bleeding diathesis, there is a high clinical suspicion for acute promyelocytic leukemia (APL). Arrange the following diagnostic and therapeutic steps in the most appropriate chronological sequence for the optimal management of this patient.

  1. 1Evaluate a peripheral blood smear for characteristic hypergranulated promyelocytes and obtain a full coagulation profile.
  2. 2Administer all-trans retinoic acid (ATRA) immediately upon morphological suspicion.
  3. 3Perform bone marrow aspiration and biopsy for definitive cytogenetic and molecular confirmation.
  4. 4Initiate definitive targeted induction therapy with arsenic trioxide and/or an anthracycline.
  5. 5Monitor closely for fever, dyspnea, and pulmonary infiltrates, initiating dexamethasone if they occur.

Answer

The correct sequence begins with morphological and coagulation evaluation, followed immediately by ATRA administration, then bone marrow biopsy for genetic confirmation, followed by full induction chemotherapy, and finally monitoring for differentiation syndrome.
The management of Acute Promyelocytic Leukemia (APL) is a highly tested exception in oncology because the highest risk of mortality occurs within the first few days due to severe coagulopathy (DIC) and hemorrhage. Therefore, upon clinical and morphological suspicion from a peripheral blood smear, all-trans retinoic acid (ATRA) must be initiated immediately. ATRA promotes the terminal differentiation of leukemic promyelocytes, rapidly improving the coagulopathy. Definitive diagnosis via bone marrow biopsy and molecular testing (for the t(15;17) PML-RARA translocation) should only be performed after ATRA is started to avoid delaying life-saving therapy. Once confirmed, full induction therapy is given. Throughout treatment, patients must be strictly monitored for differentiation syndrome, which is managed with dexamethasone.

Step-by-Step Solution

1
Evaluate peripheral smear and coagulation profile.
Identifies morphological signs of APL (promyelocytes with multiple Auer rods) and confirms the presence or absence of DIC.
Rapid morphological assessment and DIC screening dictate the immediate need for targeted intervention.
2
Administer all-trans retinoic acid (ATRA).
Promotes terminal differentiation of leukemic promyelocytes and halts the release of procoagulants.
Early mortality in APL is overwhelmingly driven by severe bleeding. ATRA rapidly reverses DIC and must be given before molecular confirmation to prevent fatal hemorrhage.
3
Perform bone marrow biopsy and cytogenetics.
Confirms the diagnosis via detection of the t(15;17) PML-RARA translocation.
Definitive genetic confirmation is required to commit the patient to a prolonged course of targeted leukemia therapy.
4
Initiate full induction chemotherapy.
Adds agents like arsenic trioxide or anthracyclines to the ATRA regimen.
While ATRA resolves the coagulopathy and differentiates cells, it is not curative alone and requires combined agents for complete leukemic eradication.
5
Monitor for and treat differentiation syndrome.
Early administration of dexamethasone if respiratory distress, weight gain, or fever occurs.
Differentiation syndrome is a life-threatening complication of ATRA therapy that typically occurs days to weeks into treatment as leukemic cells mature.

Key Concept

In patients with suspected acute promyelocytic leukemia (APL), all-trans retinoic acid (ATRA) must be administered immediately based on clinical and morphological (peripheral smear) suspicion to prevent fatal hemorrhage from DIC, prior to obtaining definitive cytogenetic confirmation via bone marrow biopsy.
Rate this question

Topics

Hematology and Oncology

More questions from this topic